Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.08), Briefing.com reports. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.47 million. During the same period last year, the company earned ($0.94) earnings per share. The firm’s revenue was down 59.6% compared to the same quarter last year.
Crinetics Pharmaceuticals Stock Performance
NASDAQ:CRNX traded down $3.10 during trading hours on Friday, hitting $47.64. The stock had a trading volume of 965,885 shares, compared to its average volume of 833,317. The business’s 50 day moving average is $48.51 and its 200-day moving average is $45.08. The company has a market cap of $3.76 billion, a price-to-earnings ratio of -12.60 and a beta of 0.68. Crinetics Pharmaceuticals has a one year low of $15.76 and a one year high of $55.78.
Insider Transactions at Crinetics Pharmaceuticals
In other Crinetics Pharmaceuticals news, insider Stephen F. Betz sold 3,000 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $47.49, for a total value of $142,470.00. Following the completion of the sale, the insider now directly owns 86,643 shares in the company, valued at $4,114,676.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Crinetics Pharmaceuticals news, CFO Marc Wilson sold 32,129 shares of Crinetics Pharmaceuticals stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $43.61, for a total value of $1,401,145.69. Following the sale, the chief financial officer now owns 111,092 shares of the company’s stock, valued at approximately $4,844,722.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephen F. Betz sold 3,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $47.49, for a total value of $142,470.00. Following the transaction, the insider now directly owns 86,643 shares of the company’s stock, valued at $4,114,676.07. The disclosure for this sale can be found here. Insiders have sold a total of 170,016 shares of company stock valued at $8,320,842 over the last three months. 6.00% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
Get Our Latest Stock Report on Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Company Profile
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
See Also
- Five stocks we like better than Crinetics Pharmaceuticals
- What is a buyback in stocks? A comprehensive guide for investors
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Where Do I Find 52-Week Highs and Lows?
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.